As a late-stage data showdown from NASH drug developers Gilead $GILD, Intercept $ICPTand France’s Genfit (EuroNext: $GNFT) looms, the Lille-based drug developer on Thursday reported positive phase II data on its drug elafibranor in patients with primary biliary cholangitis (PBC), a rare and progressive liver disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,